Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy
J Thorac Oncol
.
2025 Jan;20(1):34-38.
doi: 10.1016/j.jtho.2024.11.004.
Authors
Dipesh Uprety
1
,
Anja C Roden
2
,
Solange Peters
3
Affiliations
1
Department of Medical Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan. Electronic address:
[email protected]
.
2
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
3
Department of Medical Oncology, Lausanne University Hospital, Lausanne, Switzerland.
PMID:
39794104
DOI:
10.1016/j.jtho.2024.11.004
No abstract available
Publication types
Editorial